A plain-language guide

Duchenne muscular dystrophy

What is known, what is still uncertain, and what is actively debated, written plainly, and built only from published medical research.

Early map · 10 sourced statements Every statement names its source Updated 2026-06-12
Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. Duchenne muscular dystrophy is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What it is

Duchenne muscular dystrophy is a severe inherited muscle disease caused by mutations in the dystrophin (DMD) gene. Without working dystrophin, muscle is gradually damaged and replaced, causing progressive weakness from early childhood.

Signs and symptoms

Calf muscle pseudohypertrophy

Enlarged-looking calves (calf pseudohypertrophy) are characteristic; the muscle is being replaced by fat and fibrous tissue rather than being strong.

Limited evidenceSource: OMIM:310200
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41439068
Notesplain_language confirmed from PMID:41439068 via curation 2026-06-12.
Last reviewed2026-06-12

Elevated circulating creatine kinase activity

A markedly raised blood level of creatine kinase (CK), an enzyme released from damaged muscle, is an early clue and is often very high in this condition.

Limited evidenceSource: OMIM:310200
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41439068
Notesplain_language confirmed from PMID:41439068 via curation 2026-06-12.
Last reviewed2026-06-12

Loss of ambulation

Walking ability is gradually lost, on average in the early teens, after which a wheelchair is needed.

Limited evidenceSource: OMIM:310200
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41911965
Notesplain_language confirmed from PMID:41911965 via curation 2026-06-12.
Last reviewed2026-06-12

Dilated cardiomyopathy

The heart muscle is also affected over time, leading to a dilated cardiomyopathy that needs regular monitoring.

Limited evidenceSource: OMIM:310200
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41037163
Notesplain_language confirmed from PMID:41037163 via curation 2026-06-12.
Last reviewed2026-06-12

X-linked recessive inheritance

Duchenne muscular dystrophy is inherited in an X-linked recessive pattern, which is why it predominantly affects boys, with the gene change carried on the X chromosome.

Limited evidenceSource: OMIM:310200
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41037163
Notesplain_language confirmed from PMID:41037163 via curation 2026-06-12.
Last reviewed2026-06-12

Muscle weakness

Progressive weakness of the muscles closest to the trunk (hips, thighs, shoulders) usually appears in early childhood and is the core feature.

Limited evidenceSource: OMIM:310200
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41439068
Notesplain_language confirmed from PMID:41439068 via curation 2026-06-12.
Last reviewed2026-06-12

Gowers sign

A 'Gowers sign', using the hands to push up the legs when rising from the floor, is a classic early sign of the hip and thigh weakness.

Limited evidenceSource: OMIM:310200
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41439068
Notesplain_language confirmed from PMID:41439068 via curation 2026-06-12.
Last reviewed2026-06-12

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

Glucocorticoids

Glucocorticoids (corticosteroids such as prednisone or deflazacort) are the mainstay of treatment and can slow the loss of muscle strength, though they carry significant side effects.

Used to help with: Duchenne muscular dystrophy.

Limited evidenceSource: PMID:41894886
The source text this rests on
“Long-term glucocorticoid therapy is the mainstay of treatment for individuals with Duchenne muscular dystrophy (DMD) but confers significant side effects.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:41894886 via curation 2026-06-12
Last reviewed2026-06-12

Turn this into questions for your doctor

The hardest part is often knowing what to ask. PatientLead Health helps families turn what is on this page into the right questions for their care team.

Prepare for your appointment with PatientLead Health →

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.
Strong evidenceBacked by solid, repeated research.
Moderate evidenceReasonable evidence, still being confirmed.
Limited evidenceSome evidence, but not yet convincing.
Early evidenceAn early finding that needs more study.
Experts disagreeResearchers actively disagree about this.

Where this comes from

This guide is built from 2 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

OMIM:310200 · Orphanet/HPO annotations for Duchenne muscular dystrophy
PMID:41894886 · From case to caution: hyponatremia in a patient with Duchenne muscular dystrophy on vamorolone and lessons for clinician